A Democrat-sponsored bill could help solve some of the vexing problems that plague the FDA’s accelerated approval program, allowing it to still bring important new medicines to market quickly, but also increasing the agency’s ability to boot ineffective drugs off the shelves, according to a perspective published in The New England Journal of Medicine.
Source: Drug Industry Daily